Vancouver, British Columbia--(Newsfile Corp. - September 18, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce the start of efficacy testing of the first two mRNA formulations from its strategic collaboration with NanoVation Therapeutics Inc. ("NanoVation Therapeutics").

As previously disclosed, ME Therapeutics aims to enhance the precision and efficacy of myeloid cell-delivered mRNA therapeutics in vivo to develop potential new cancer therapies by leveraging the cutting-edge lipid nanoparticle (LNP) technologies of NanoVation Therapeutics. NanoVation Therapeutics' next-generation lipid nanoparticle platforms enable the efficient nucleic acid delivery to a variety of tissues. To efficiently target immune cells, NanoVation Therapeutics has rationally designed and further optimized its long-circulating LNP (lcLNP?) technology. NanoVation Therapeutics has initiated numerous programs across multiple RNA modalities.

"The speed at which we were able to go from announcing our research collaboration to having a testable drug demonstrates the potential of mRNA as a rapidly developable therapeutic modality to potentially treat cancer and other diseases," said Salim Dhanji, PhD, Chief Executive Officer of ME Therapeutics. "These initial studies will increase our understanding of the therapeutic potential of mRNA delivery to myeloid cells for the treatment of cancer."

Myeloid Enhancement (ME) Therapeutics is a preclinical stage, Vancouver based biotechnology company involved in the discovery and development of novel immuno-oncology therapeutics targeting immune suppression in cancer. Our focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells to enhance anti-cancer immunity. For more information, please visit https://www.metherapeutics.com and the Company's profile on SEDAR+ at https://www.sedarplus.ca.

ON BEHALF OF THE BOARD

"Salim Dhanji"
Dr. Salim Dhanji
Chief Executive Officer and Director

For further information, please contact:
Dr. Salim Dhanji
Telephone: (236) 516-7714

Neither the Canadian Securities Exchange nor any Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements